Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Assessment Of Bleomycin Pulmonary Toxicity In Men With Poor-Prognosis Non-Seminomatous Germ-Cell Tumors Treated In The Getug 13 Phase Iii Trial

N. Naoun,G. Le Teuff,L. Pagliaro,A. Flechon,J. Mardiak,L. Geoffrois,P. Kerbrat,C. M. Chevreau,R. Delva,F. Rolland,C. Theodore,G. Roubaud,G. Gravis,J-C. Eymard,J. P. Malhaire,C. Linassier,M. Reckova,S. Nenan,S. Culine,K. Fizazi

ANNALS OF ONCOLOGY（2021）

Cited 0|Views19
No score
Abstract
In 2014, the GETUG 13 trial has established the role of early intensified treatment for men with poor prognosis germ-cell tumors (GCT) and unfavorable tumor marker decline (Fizazi K, Lancet Oncol 2014). Patients with unfavorable marker decline were randomized after 1 cycle of BEP to receive either 3 additional BEP or dose-dense chemotherapy with personalized cumulative doses of bleomycin (potentially exceeding the 300 mg recommended threshold) based on serial lung function assessments. We assessed pulmonary toxicity of this strategy.
More
Translated text
Key words
bleomycin,pulmonary toxicity,tumors,poor-prognosis,non-seminomatous,germ-cell
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined